Orion Corporation (Finnish company) Staying Ahead in a Competitive Market

Orion Corporation, a Finnish company, has been making significant strides in the competitive market. They are a leading player in the pharmaceutical industry, with a wide range of products including prescription medicines, consumer health products, and animal health products.

Orion Corporation has a strong presence in the Nordic region, with operations in Finland, Sweden, and other countries. Their products are widely available in many countries, including Europe, Asia, and the Americas.

One of the key factors contributing to Orion Corporation's success is their commitment to innovation. They invest heavily in research and development, with a focus on creating new and improved products that meet the changing needs of their customers.

Orion Corporation's dedication to quality and safety has earned them a reputation as a trusted partner in the pharmaceutical industry.

Take a look at this: Orion Classics

Orion Corporation's business operations are built on a strong foundation of R&D and manufacturing. They have a significant presence in the Nordic market, with a large share of their revenue coming from Finland.

Their business is divided into three main areas: Human Health, Food and Ingredients, and Consumer Products. Orion's Human Health segment is the largest, accounting for about 70% of their revenue.

Orion's business operations are supported by a global network of partners and suppliers.

A fresh viewpoint: Orion Breweries

Having a solid business operations strategy is crucial for any company looking to expand globally. Orion, a company in the pharmaceuticals industry, turned to TMF Group for support in several countries where they didn't have substantial in-house resources.

TMF Group helped Orion establish its corporate structures correctly and handle accounting and payroll needs efficiently and compliantly, in line with local rules and regulations. This ensured that Orion's expansion was smooth and hassle-free.

One of the biggest benefits of working with TMF Group is the support provided by their global account manager. This central point of contact helps resolve local issues and provides coordination at a global level.

Having a single point of contact can make a huge difference in reducing complexity for a company like Orion.

Additional reading: Contact Energy

Orion invests around 15% of its net sales in pharmaceutical research and development. This significant investment is a testament to the company's commitment to innovation and growth.

Orion's R&D efforts focus on early-stage studies, including preclinical and first and second clinical stages. This approach allows the company to identify promising new treatments and bring them to market more quickly.

Research is conducted across all of Orion's therapeutic areas, including central nervous system drugs, anticancer and intensive care drugs, and inhaled drugs. The company's Easyhaler technology is a notable example of this.

Orion is also exploring veterinary and concomitant medications, expanding its reach into new areas.

The company's key clinical development projects include Darolutamide, an antiandrogen used to treat prostate cancer, and ODM-109, an orally administered levosimendan for ALS disease treatment.

Some of the other notable projects include ODM-203, a FGFR + VEGFR inhibitor, ODM-207, a BET protein inhibitor, and ODM-208 and ODM-209, CYP11A1 inhibitors.

Here are some of Orion's key clinical development projects:

Orion Corporation has a long-standing experience in the field of neurological diseases, making it a strong commercial partner.

In December 2023, Navamedic and Orion Corporation signed a non-binding term sheet for a licensing- and supply agreement for Flexilev®, a novel prescription treatment for Parkinson’s disease.

This agreement will grant Orion the exclusive right to market, distribute, and sell Flexilev® in 27 countries in Europe, including the "big five": Germany, France, Italy, Spain, and the UK.

The intended licensing agreement will consist of a non-refundable upfront payment of 2mEUR to Navamedic, upon signature of the agreement.

Orion will also be granted the right to use Navamedic’s trademarks for the product, and will assume all rights and responsibilities as the marketing authorization (MA) holder in their territory.

Navamedic is entitled to milestone payments of up to 3.5 mEUR upon reimbursement approval in key countries, as well as royalties, and sales milestone payments.

The final agreement is expected to be signed by the end of the first quarter of 2024.

For your interest: Cassa Centrale Banca - Credito Cooperativo Italiano